Abstract
BackgroundImmune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is the most common rheumatic adverse effect of cancer immunotherapy. Patients have dramatically different trajectories; some have a mild self-limited course, while others have...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
